Want to see IN:INDSWFTLAB full AI Analyst Report?
INDSWFTLAB Stock Chart & Stats
₹90.70
-₹2.17(-1.99%)
At close: 4:00 PM EST
₹90.70
-₹2.17(-1.99%)
Day’s Range― - ―
52-Week Range₹87.00 - ₹247.80
Previous CloseN/A
Volume31.71K
Average Volume (3M)7.30K
Market Cap
₹20.44B
Enterprise Value₹10.02B
Total Cash (Recent Filing)₹4.72B
Total Debt (Recent Filing)₹205.01M
Price to Earnings (P/E)46.9
Beta0.94
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.26
Shares Outstanding86,961,555
10 Day Avg. Volume7,859
30 Day Avg. Volume7,299
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)0.79
Price to Sales (P/S)1.71
P/FCF Ratio-10.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Balance SheetManagement materially reduced leverage and grew equity through 2024–2026, creating a stronger capital base. Lower debt and higher equity increase financial flexibility, reduce refinancing risk, and provide a durable buffer to absorb shocks and support strategic investments.
Historic Revenue ExpansionMulti-year top-line growth through 2021–2024 indicates the company can scale its products and capture market demand. That historical traction implies underlying commercial capability that could be re-leveraged if operational issues driving the 2025–2026 contraction are addressed.
Prior Cash-generation CapabilityThe firm demonstrated the ability to convert earnings into cash during 2021–2023. This track record suggests cash-generation can be restored through margin, working-capital, or operational fixes, giving a durable path to normalize funding of capex and growth without permanent reliance on external capital.
Bears Say
Weak Cash GenerationPersistent negative operating and free cash flow across 2024–2026 creates a structural funding gap. This reduces the company's ability to self-fund operations and growth, heightens liquidity and refinancing risk, and constrains durable investment in R&D, manufacturing or market expansion.
Revenue And EBIT DeteriorationA sustained top-line decline and materially weaker operating profit undermine scale economics and margin sustainability. If demand or pricing pressure persists, the company may face prolonged margin compression, reduced reinvestment capacity, and a weaker competitive position over the medium term.
Earnings Volatility & Profit-to-cash MismatchVolatile earnings and a disconnect between reported profits and cash flow impair forecasting and capital-allocation decisions. Persistent profit-to-cash mismatch suggests working-capital or one-time items could recur, reducing predictability and making durable planning and investor confidence more difficult.
Ind-Swift Laboratories Ltd. News
INDSWFTLAB FAQ
What was Ind-Swift Laboratories Ltd.’s price range in the past 12 months?
Ind-Swift Laboratories Ltd. lowest stock price was ₹87.00 and its highest was ₹247.80 in the past 12 months.
What is Ind-Swift Laboratories Ltd.’s market cap?
Ind-Swift Laboratories Ltd.’s market cap is ₹20.44B.
When is Ind-Swift Laboratories Ltd.’s upcoming earnings report date?
Ind-Swift Laboratories Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 32 days.
How were Ind-Swift Laboratories Ltd.’s earnings last quarter?
Ind-Swift Laboratories Ltd. released its earnings results on May 28, 2026. The company reported ₹1.81 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.81.
Is Ind-Swift Laboratories Ltd. overvalued?
According to Wall Street analysts Ind-Swift Laboratories Ltd.’s price is currently Overvalued.
Does Ind-Swift Laboratories Ltd. pay dividends?
Ind-Swift Laboratories Ltd. pays a Annually dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Ind-Swift Laboratories Ltd. dividends here
What is Ind-Swift Laboratories Ltd.’s EPS estimate?
Ind-Swift Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ind-Swift Laboratories Ltd. have?
Ind-Swift Laboratories Ltd. has 86,961,555 shares outstanding.
What happened to Ind-Swift Laboratories Ltd.’s price movement after its last earnings report?
Ind-Swift Laboratories Ltd. reported an EPS of ₹1.81 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Ind-Swift Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:INDSWFTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories Limited, an Indian enterprise, is engaged in the development, production, and distribution of active pharmaceutical ingredients (APIs). The company's comprehensive API portfolio addresses numerous therapeutic domains, including macrolide antibiotics, cardiovascular ailments, antihistamines, antidiabetics, antipsychotics, bone resorption inhibitors, antimigraine treatments, Parkinson's disease, hyperparathyroidism, analgesics, aromatase inhibitors, nootropics, antidiarrhoeal/antiprotozoal conditions, anticholinergics, sedatives, hypnotics, alcohol abstinence, antineoplastics, and solutions for ADHD symptoms. Additionally, Ind-Swift supplies reference standards and impurities for a long list of specific compounds such as acamprosate calcium, anastrozole, aripiprazole, atorvastatin calcium, bexarotene, cinacalcet hydrochloride, clarithromycin, ezetimibe, fexofenadine hydrochloride, imatinib mesylate, ivabradine hydrochloride, ivabradine oxalate, letrozole, mecloxamine citrate, naratriptan hydrochloride, nitazoxanide, quetiapine, ropinirole hydrochloride, rosuvastatin calcium, saxagliptin monohydrate, silodosin, and temozolomide. Beyond its core manufacturing operations, the company offers a broad spectrum of services. These encompass early and late-phase drug development, process research and development, contract and API manufacturing, custom chemicals and synthesis, analytical development, regulatory support, specialized chemistry services, impurity profiling, isolation, discovery, identification, characterization, and project management. Founded in 1995, and headquartered in Manimajra, India, Ind-Swift Laboratories Limited also exports its products internationally.
Technical Analysis
Hikal Limited
―
Indoco Remedies Limited
―
Lincoln Pharmaceuticals Ltd
―
Solara Active Pharma Sciences Ltd.
―
Venus Remedies Limited
―